This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Original Research

A Randomized Controlled Pilot Study on Mindfulness-Based Cognitive Therapy for Unipolar Depression in Patients With Chronic Pain

Marasha de Jong, MD; Frenk Peeters, MD, PhD; Tim Gard, PhD; Heidi Ashih, MD, PhD; Jim Doorley, BA; Rosemary Walker, BA; Laurie Rhoades, LICSW; Ronald J. Kulich, PhD; Karsten D. Kueppenbender, MD; Jonathan E. Alpert, MD, PhD; Elizabeth A. Hoge, MD; Willoughby B. Britton, PhD; Sara W. Lazar, PhD; Maurizio Fava, MD; and David Mischoulon, MD, PhD

Published: February 28, 2017

Article Abstract

Objective: Chronic pain is a disabling illness, often comorbid with depression. We performed a randomized controlled pilot study on mindfulness-based cognitive therapy (MBCT) targeting depression in a chronic pain population.

Method: Participants with chronic pain lasting ≥ 3 months; DSM-IV major depressive disorder (MDD), dysthymic disorder, or depressive disorder not otherwise specified; and a 16-item Quick Inventory of Depressive Symptomatology-Clinician Rated (QIDS-C16) score ≥ 6 were randomly assigned to MBCT (n = 26) or waitlist (n = 14). We adapted the original MBCT intervention for depression relapse prevention by modifying the psychoeducation and cognitive-behavioral therapy elements to an actively depressed chronic pain population. We analyzed an intent-to-treat (ITT) and a per-protocol sample; the per-protocol sample included participants in the MBCT group who completed at least 4 of 8 sessions. Changes in scores on the QIDS-C16 and 17-item Hamilton Depression Rating Sale (HDRS17) were the primary outcome measures. Pain, quality of life, and anxiety were secondary outcome measures. Data collection took place between January 2012 and July 2013.

Results: Nineteen participants (73%) completed the MBCT program. No significant adverse events were reported in either treatment group. ITT analysis (n = 40) revealed no significant differences. Repeated-measures analyses of variance for the per-protocol sample (n = 33) revealed a significant treatment × time interaction (F1,31 = 4.67, P = .039, η2p = 0.13) for QIDS-C16 score, driven by a significant decrease in the MBCT group (t18 = 5.15, P < .001, d = >1.6), but not in the control group (t13 = 2.01, P = .066). The HDRS17 scores did not differ significantly between groups. The study ended before the projected sample size was obtained, which might have prevented effect detection in some outcome measures.

Conclusions: MBCT shows potential as a treatment for depression in individuals with chronic pain, but larger controlled trials are needed.

Trial Registration: identifier: NCT01473615′ ‹’ ‹

Volume: 78

Quick Links: Neurologic and Neurocognitive , Neurology

Continue Reading…

Subscribe to read the entire article


Buy this Article as a PDF


Sign-up to stay
up-to-date today!


Already registered? Sign In

Original Research

Telehealth of Coordinated Specialty Care in Early Psychosis During COVID-19

As the COVID-19 pandemic emerged in 2020, access to in-person clinical care was restricted. This study explored...